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We have previously reported that the loss of Arx and/
or Pax4 gene activity leads to a shift in the fate of the
different endocrine cell subtypes in the mouse
pancreas, without affecting the total endocrine cell
numbers. Here, we conditionally and ectopically
express Pax4 using different cell-specific promoters
and demonstrate that Pax4 forces endocrine pre-
cursor cells, as well as maturea cells, to adopt a b cell
destiny. This results in a glucagon deficiency that
provokes a compensatory and continuous glucagon+
cell neogenesis requiring the re-expression of the pro-
endocrine gene Ngn3. However, the newly formed
a cells fail to correct the hypoglucagonemia since
they subsequently acquire a b cell phenotype upon
Pax4 ectopic expression. Notably, this cycle of neo-
genesis and redifferentiation caused by ectopic
expression of Pax4 in a cells is capable of restoring
a functionalbcell mass and curing diabetes in animals
that have been chemically depleted of b cells.
INTRODUCTION
The endocrine pancreas is organized in islets of Langerhans
comprising five original cell subtypes, a, b, d, 3, and PP cells,
secreting glucagon, insulin, somatostatin, ghrelin, and pancreatic
polypeptide (PP), respectively (Collombat et al., 2006). The
identification and characterization of the genetic determinantsunderlying endocrine pancreas morphogenesis and regeneration
may potentially aid the design of cell replacement therapies to
treat type 1 and 2 diabetes. In this context, a number of studies
have demonstrated that, during development, the cooperation
of several transcription factors successively specifies progenitor
cells toward the pancreatic, endocrine, and ultimately islet cell
fates. Hence, Pdx1 is required for pancreatic epithelium determi-
nation (Ahlgren et al., 1996, 1998; Grapin-Botton et al., 2001;
Jonsson et al., 1994; Offield et al., 1996) and subsequently Neuro-
genin3 (Ngn3) for endocrine lineage specification (Gradwohl
et al., 2000; Gu et al., 2002; Jensen et al., 2000; Johansson
et al., 2007). Next to Ngn3 induction, a complex network of tran-
scription factors, including Arx and Pax4, progressively and
differentially promotes the particular endocrine fates (Collombat
et al., 2003; Sosa-Pineda et al., 1997). In mice lacking Arx, the
b and d cell fates were found favored at the expense of a cell
genesis, while the total endocrine cell content remained normal
(Collombat et al., 2003). Conversely, in the absence of Pax4, the
opposite phenotype was observed (Sosa-Pineda et al., 1997),
indicating an inhibitory, cross-regulatory circuit between Arx
and Pax4 (Collombat et al., 2005). Additional findings supported
these conclusions and suggested that, first, Arx and Pax4 instruct
endocrine precursor cells toward either an a cell or a b/d cell fate,
respectively. Next, through the analysis of double-mutant mice,
a secondary function of Pax4 in specifying the b cell lineage in
b/d precursor cells was uncovered (Collombat et al., 2005).
Recent evidence has demonstrated that the forced expression
of Arx in early pancreatic cells drives endocrine progenitors
toward either an a or, surprisingly, a PP cell fate (Collombat
et al., 2007). It was therefore concluded that Arx is not only neces-
sary, but also sufficient to instruct the a and PP cell lineages.Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc. 449
Figure 1. The Ectopic Expression of Pax4 in Pdx1 or Pax6 Expression Domains Promotes the Genesis of Oversized Islets Mainly Containing
Insulin-Expressing Cells
(A) Characterization of the life span and glycemia (in mg/dl) of POE::Pdx1cre and POE::Pax6cre mice 1 day and 6 weeks postpartum, as well as shortly before
death (SBD). Note that initially, these animals are hypo- and subsequently hyperglycemic.
(B–P) Immunohistochemical analysis of the islets of double-transgenic mice. A dramatic increase in islet size and insulin-expressing cell mass is evident 6 weeks
postpartum (C, F, I, L, and O) and is even more pronounced SBD (D, G, J, M, and P) as compared to representative control islets (B, E, H, K, and N). Concurrently,450 Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc.
Of particular interest was the finding that the forced expres-
sion of Arx in adult b cells induced their conversion into cells
exhibiting a or PP cell phenotypes (Collombat et al., 2007).
This discovery was of fundamental importance in the context
of b cell-based therapy and implied that the opposite conversion
might be achieved, that is, generation of b cells from other endo-
crine cells. To test this hypothesis, we generated mice condition-
ally expressing the Pax4 gene. Our data indicate that the ectopic
expression of Pax4 in early pancreatic cells, and also in a cells,
induces their respecification toward a b cell fate or identity. As
a consequence of the ensuing glucagon deficiency, an ongoing
neogenesis of a cells occurs. However, such a cells are contin-
uously converted into b cells upon Pax4 ectopic expression, re-
sulting in the development of oversized islets of Langerhans.
Importantly, a prominent expression of the proendocrine tran-
scription factor Ngn3 in the pancreas of such animals is high-
lighted. Our results are consistent with the recently reported
notion of facultative adult stem cells that reactivateNgn3 expres-
sion in injured pancreas (Xu et al., 2008). Finally, after streptozo-
tocin (STZ)-induced depletion of b cells in young mice ectopically
expressing Pax4, an a cell-mediated regeneration of the b cell
mass, a progressive normalization of the glycemia, and an
extended life span are observed.
RESULTS
Pax4 Ectopic Expression in the Developing Pancreas
Promotes the Genesis of Oversized Islets Mainly
Composed of b Cells
Taking advantage of the Cre-LoxP system, we generated trans-
genic mice able to conditionally express the Pax4 gene (POE).
Briefly, the construct used included the cytomegalovirus en-
hancer/chicken b-actin (CAG) promoter driving the expression
of the eGFP gene followed by translation stop codons in all three
frames and flanked by LoxP sites (Figure S1A available online). A
Pax4 cDNA-IRES-b-galactosidase sequence was subsequently
cloned downstream of eGFP. Using pronuclear injection, we
derived five independent transgenic mouse lines. The resulting
mice constitutively expressed eGFP, but not b-galactosidase,
at all ages examined (Figures S1B–S1E).
POE animals were bred with Pdx1cre or Pax6cre animals to
target Pax4 expression to the pancreatic epithelium or the endo-
crine tissue, respectively (Ashery-Padan et al., 2004; Gu et al.,
2002). Double-transgenic POE::Pdx1cre and POE::Pax6cre
mice were born and developed normally. However, animals of
both genotypes eventually died at the age of 3 to 12 weeks, a
majority after 9 weeks (Figure 1A and data not shown). To assess
whether the ectopic expression of Pax4 altered glucose homeo-
stasis, we measured blood sugar levels. One day postpartum,
a decrease in glycemia was evident in both POE::Pdx1cre and
POE::Pax6cre genotypes (Figure 1A). Notably, at 6 weeks of
age, blood glucose levels were found to be normal in thesesame animals compared to controls, whereas shortly before
death (SBD), a dramatic hyperglycemia was uncovered. This
indicates that POE::Pdx1cre and POE::Pax6cre mice initially
present a hypoglycemic condition that progressively evolves
toward a hyperglycemic one.
To assess the consequences of the forced expression of Pax4
in Pdx1 and Pax6 expression domains, we performed immuno-
histochemical analyses of double-transgenic pancreata. As
similar results were obtained in POE::Pax6cre and POE::Pdx1-
cre mice, pictures representative of both genotypes are dis-
played for 6-week-old animals (Figures 1C, 1F, 1I, 1L, and 1O)
and SBD (Figures 1D, 1G, 1J, 1M, and 1P). We did not observe
any change in endocrine cell composition in POE animals as
compared to their wild-type counterparts (Figures 1B, 1E, 1H,
1K, and 1N, and data not shown). The analysis of both POE::
Pax6cre and POE::Pdx1cre pancreata showed a dramatic
increase in islet size (note the 2- and 8-fold scale reduction in
magnification in Figures 1C, 1F, 1I, 1L, and 1O and in Figures
1D, 1G, 1J, 1M, and 1P, respectively; Figures S2 and S3) con-
taining mainly insulin-expressing cells (Figures 1F, 1G, 1O, 1P,
S2, and S3) and only few d- and Arx-labeled a and PP cells
(Figures 1F, 1G, 1I, 1J, 1L, 1M, 1O, and 1P). Notably, the remain-
ing a, d, and PP cells were consistently located at one pole of the
islet of Langerhans (Figures 1F, 1G, 1I, 1J, 1L, 1M, 1O, and 1P),
a subset of these coexpressing the glucagon and somatostatin
or PP hormones (arrows in Figures 1I and 1L, respectively). A
quantification of these alterations (Figure 1Q, Table S1) ascer-
tained (1) an age-dependent increase in islet size and b cell
mass, concurrently with a reduction in non-b cell numbers (rela-
tive as well as absolute numbers), and (2) an abnormal location of
the few remaining a, d, and PP cells at one pole of the islet.
Pax4 expression was assayed with a newly developed anti-
body that detected Pax4 in wild-type embryonic pancreata
(Wang et al., 2008) and specifically in adult b cells (Figures
S4A, S4B, S5A, and S5D), as previously reported (Theis et al.,
2004). Neither in Pax4-depleted nor in Ngn3-deficient islets did
we find any expression of Pax4 (Figures S4C and S4D and
data not shown). Importantly, in POE::Pax6cre mice, most
insulin-producing cells were found positive for Pax4 (Figures
S5E–S5H), whereas the vast majority of pancreatic cells were
labeled in POE::Pdx1cre animals (Figures S5I–S5L). These
results were confirmed by RT-PCR analysis (Figure S6) and
assessment of b-galactosidase activity (Figures S1F and S1G).
Further examination of POE::Pax6cre and POE::Pdx1cre mice
during the development of the endocrine pancreas indicated that
a, d, and PP cell lineages were disfavored to the benefit of an
insulin-producing cell fate (Figures 2A–2H). Most insulin-labeled
cells present in double-transgenic mice correctly expressed
the b cell specific markers Nkx6.1, Pdx1, Glut2, and HB9
(Figures 2K–2P and data not shown). Accordingly, they lacked
Arx (Figures 2I and 2J) and Brn4 (Figures 2Q and 2R), labeling
a/PP and a cells, respectively, whereas Pax6 and Isl1 werea loss of a- (E–M), d- (H–J), PP- (K–M), and Arx-labeled (N–P) cells is evident, but, interestingly, few of these remain detectable at one pole of the islet, some
coexpressing the glucagon and somatostatin (arrow in I) or PP (arrow in L) hormones.
(Q) A quantification of the endocrine cell alterations ascertains these observations (also see Table S2).
For the purpose of clarity, the magnification of double-transgenic islets is twice (C, F, I, L, and O) or eight times (D, G, J, M, and P) reduced compared to that of
controls. (n > 11, *p < 0.05, **p < 0.01, ***p < 0.001; all values are expressed as means ± standard error of the mean).Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc. 451
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detected in all islet cell types, as expected (Figures 2S and 2T,
and data not shown). To further assess the function of these
insulin-producing cells postnatally, we performed glucose toler-
ance tests associated with systemic insulin measurements.
Consistent with the increased b cell mass we previously noted,
3-week-old POE::Pdx1cre and POE::Pax6cre mice displayed
an improved glucose clearance associated with a more than
2-fold increase in circulating insulin levels (Figure 2U). Alto-
gether, our findings suggest that the ectopic expression of the
Pax4 gene drives endocrine precursor cells almost exclusively
toward an insulin-expressing cell fate, and that these cells exhibit
a functional b cell phenotype.
Conversion from an a to a b Cell Phenotype
As Pax4 specifically favors the b cell fate and identity throughout
the morphogenesis of theendocrine tissue, wewondered whether
this might also apply to mature endocrine cells. Therefore, animals
conditionally expressing Pax4 in glucagon-producing cells (Her-
rera, 2000) (Figure S8) were generated (POE::Glucre), and endo-
crine cell numbers were monitored. As early as 1 week post-
partum, a 50% enlargement in islet size was outlined, these
containing increased numbers of insulin+/Pax4+ cells compared
to controls (Figure 3A). Notably, the content of glucagon-
producing cells was found to be reduced by 77%, and most of
the remaining glucagon+ cells were located at one pole of the islet
(Figures 3A–3C). As expected, d and PP cell numbers were
unchanged (Figures 3B and 3C). It is worth noticing that the
expression of Pax4 in glucagon-producing cells was accompa-
niedby theproductionof theb-galactosidase protein (Figure S1A),
allowing lineage-tracing experiments. One week after birth, this
otherwise glucagon-cell-specific labeling was detected in the
majority of insulin-producing cells (Figures 3D–3F) expressing
a typical b cell complement of transcription factors (Table S2).
Very few cells were found positive for both insulin and glucagon
(Figure S9G). Besides, we observed an age-dependent increase
in islet size and in the number of insulin-/b-galactosidase-
producing cells, the latter exhibiting most b cell features (Tables
S2 and S3, Figures 3G–3I and 2U). This suggests that, upon
Pax4 ectopic expression, adult glucagon-expressing cells are
continuously converted into cells exhibiting a b cell phenotype.
Pax4 Ectopic Expression in b Cells Does Not Induce
Their Proliferation
To further characterize the origin of the supernumerary b cells,
we assayed proliferating cells combining bromodeoxyuridine
(BrdU) incorporation and Ki67 staining. After a BrdU pulse in
5-week-old POE::Glucre mice, pancreata were quantitativelyanalyzed 1 week later, and a significant 2.35-fold increase in
the number of BrdU-labeled cells was detected as compared
to controls (Table S4). Interestingly, most BrdU+ (Figure S9F),
but also Ki67+ (Figure S9D) cells were located outside the islets,
within or adjacent to the neighboring duct epithelium.
The cell-autonomous effect of an augmentation of the Pax4
dose in b cells was analyzed by crossing of POE with Inscre
mice expressing the cre recombinase under the control of the
insulin promoter (Herrera, 2000). The quantification of the endo-
crine cell numbers in 3-week-old POE::Inscre pancreata did not
reveal any increase in b cell numbers, or in islet size (Figure S10
and data not shown), despite the use of the POE mouse line
inducing the highest Pax4 expression (Table S5, line 5). Thus,
although Pax4 may promote a modest proliferation of b cells in
rat islet cultures (Brun et al., 2004), alternative mechanisms
clearly act to boost the robust expansion of the b cell mass
consistently observed in POE::Pdx1cre, POE::Pax6cre, and
POE::Glucre mice (from hereon termed ‘‘double-transgenic
animals’’). One issue of concern to our approach was related
to the overexpression of Pax4. However, through the use of
different POE transgenic founder mice, we demonstrated that
the ectopic expression of Pax4 at a dose lower than found in
normal b cells is sufficient to induce a loss of the a cell phenotype
to the benefit of b cell features (Table S5).
Rescuing Glucagon Deficiency Prevents the Generation
of Oversized Islets
As lineage-tracing experiments demonstrated that glucagon-
expressing cells were converted into cells displaying a b cell
phenotype, a depletion of a cells was expected. However, we
consistently detected clusters of glucagon+ cells in our double-
transgenic mice (Figures 1–3), suggesting that a cell neogenesis
occurred. We therefore hypothesized that the latter might
be driven by the hypoglucagonemia resulting from the a to
b cell conversion. To test this theory, we injected 3-week-old
POE::Pdx1Cre, POE::Glucre, POE::Pax6cre, and control ani-
mals twice daily with glucagon during 3 weeks. A significant
decrease in islet size was observed in glucagon-treated animals
as compared to controls (Figure 4). This was mainly attributed to
a reduction in the b cell mass (Figures 4E and 4G compared to
Figure 4C, and Figure 4K compared to Figure 4I; Tables S3
and S4). Importantly, the number of a cells was also found to
be significantly diminished (Figures 4F, 4H, and 4L and Tables S3
and S4). These results thus indicate that decreased glu-
cagon levels are responsible for the continuous replenishment
of a cells that acquire a b cell phenotype in double transgenic
animals.Figure 2. Insulin-Expressing Cells Detected in POE::Pdx1cre and POE::Pax6cre Pancreata Rxhibit a b Cell Identity
(A–T) Characterization of POE::Pdx1cre and POE::Pax6cre hormone-expressing cells. Sections of double-transgenic pancreata (of the indicated ages) were
stained with the mentioned antibodies, and the number of labeled cells was counted and reported to the count obtained in POE control animals. The values
are expressed in percentage of change in labeled cell number compared to controls. All values are statistically significant, with p values lower than or equal
to 0.05. Note that the numbers of insulin-expressing cells are dramatically increased in double-transgenic animals at all examined stages (A–P and S–T) and
this, as early as E13 (A and B), compared to controls. Concurrently, the mean contents of a- (A, B, G–J, Q, and R), d- (C and D), PP- (E and F), and Arx- (I
and J) marked cells appear drastically reduced. A thorough analysis of endocrine cell-specific markers demonstrates that all insulin-producing cells clearly
express Pax4 (G and H), as well as the b cell markers Nkx6.1 (K and L), Glut-2 (M and N), and Pdx1 (O and P). These are negative for the a cell-specific factor
Brn-4 (Q and R), whereas, all endocrine cells express Pax6 (S and T).
(U) An improved glucose tolerance and insulin release are highlighted in 3-week-old double-transgenic mice as compared to control POE mice (n > 3, ***p < 0.001,
**p < 0.01, *p < 0.05). Each picture is representative of at least four independent animals; note that, for the purpose of clarity, a POE::Pax6cre islet is displayed in (H).Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc. 453
Requirement of Ngn3 Re-expression for a Cell
Neogenesis and Ensuing Acquisition of a b Cell
Phenotype
The location of endocrine non-b cells at one pole of the islet of
Langerhans of double-transgenic animals was remarkable.
This observation was confirmed through Z stack analysis of
POE::Pdx1Cre, POE::Glucre, and POE::Pax6cre whole islets
stained with anti-glucagon antibodies (Movie S1). Most impor-
tantly, these glucagon-labeled cell clusters were consistently
found adjacent to the ductal lining (Movie S2, in blue). The very
detection of such glucagon+ cells was intriguing as their conver-
sion into b cells was expected upon Pax4 expression. A likely
explanation may be the continuous generation of glucagon-
labeled cells, their detection indicating a transitional state prior
to their conversion into insulin-expressing cells. This hypothesis
was supported by the active cell proliferation observed near and
within the duct epithelium (Figures 5B, S9D, and S9F), close to
the pole of glucagon+ cells. In addition, scattered glucagon+ cells
were found within the lining of the duct (arrowheads in Figures 5C
Figure 3. Conversion of Glucagon-Express-
ing Cells into Insulin-Producing Cells upon
Pax4 Ectopic Expression
(A–C) Quantification of the endocrine cell content
alterations upon ectopic expression of the Pax4
gene in glucagon-producing cells in 1-week-old
animals. A clear increase in the number of insulin-/
Pax4-labeled cells at the expense of glucagon-
expressing cells is highlighted (A), whereas the
d and PP cell contents are found unchanged
(B and C). Note the accumulation of the remaining
glucagon-marked cells at one pole of the islet.
(D–F) The detection of insulin- and b-galactosi-
dase-expressing cells on serial sections demon-
strates that numerous insulin-labeled cells do
express the b-galactosidase gene that normally
marks glucagon-positive cells.
(G–I) The same observation is made in 6-week-old
animals with coimmunofluorescence. All reported
values are statistically significant (p < 0.05, n = 5).
See Table S2 for a detailed analysis.
and 5D), whereas the duct markers cyto-
keratin-19 (CK19) and SPP1 were de-
tected not only within the duct epithelium,
but also in few adjacent islet cells (arrow-
heads in Figures 5E and 5F). The exis-
tence of facultative progenitor cells in
adult mice that, under specific injury
conditions, reactivate Ngn3 expression
and develop into all four endocrine cell
types has been recently reported (Xu
et al., 2008). Interestingly, in pancreata
ectopically expressing Pax4, we also
noticed a reactivation of the islet cell
progenitor marker Ngn3 (Figures 5G,
5H, S9A, S11, and S12, and Tables S3
and S4), whilePax4 expression was never
detected in duct cells (Figure S9B).
However, because of the difficulties clas-
sically encountered to detect Ngn3 in adult tissues, the definitive
location and counts of Ngn3-producing cells will await the gener-
ation of better antibodies/in situ probes. We therefore asked
whether Ngn3 reactivation was involved in the generation of
supernumerary insulin+ cells by tracing exocrine- and Ngn3-
producing cells, or inhibiting Ngn3 expression in the pancreas
of double-transgenic mice. Because the expression of Cre,
GFP, and b-galactosidase in our double-transgenic animals
precluded the use of duct-Cre, Ngn3-Cre, Ngn3-GFP, or
Ngn3-LacZ mouse lines for tracing purposes, a lentiviral
approach was preferred. Specifically, recombinant lentiviruses
constitutively expressing a c-Myc-tagged DsRED2 reporter
were injected into the pancreatic duct of POE::Glucre mice, as
previously described (Xu et al., 2008). Because of the high inten-
sity of the GFP signal present in some animals, native DsRED2
fluorescence could not be unambiguously ascertained. We
therefore employed immunohistochemistry to detect the exoge-
nous c-Myc epitope-tag fused to DsRED2 (the endogenous
c-Myc being unrecognized; Figure 5J). Two weeks after454 Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc.
Figure 4. Exogenous Glucagon Supplementation Prevents Islet Overgrowth
Six-week-old pancreata of the indicated genotypes were sectioned and stained with anti-insulin (A, C, E, G, I, and K) or glucagon (B, D, F, H, J, and L) antibodies.
The values at the top right corner of each photograph represent the number of hormone-producing cells per square centimeter of pancreas. The counts reported
underneath each picture set represent variations in islet surface (estimated in silico), with POE::Pax6cre/Pdx1cre pancreata (C and D) used as a reference for
photographs (A)–(H) and POE::Glucre pancreata (I and J) as reference for photographs (I)–(L). Note the overall diminution in islet size and glucagon+ cell content,
as well as the drastic decrease in insulin-expressing cell number (E–H compared to C–D and K–L compared to I–J) in animals supplemented with glucagon for
3 weeks compared to untreated ones (*p < 0.05, **p < 0.01, n = 3).infection, Myc-tagged cells were noted in the vast majority of
duct and acinar cells of control animals, whereas less than 5%
of endocrine cells were labeled, as reported previously (Xu
et al., 2008) (Figure 5K). In the pancreas of double-transgenic
mice, however, 71% of endocrine cells were positive for the
Myc tag (Figure 5L), most of them expressing insulin
(Figure 5M) and b-galactosidase (Figures 5N and 5O), the latter
labeling cells that previously expressed glucagon. This result
suggests that exocrine cells were converted into endocrine cellsin the double-transgenic mice. Double-transgenic mice were
also infected with recombinant lentiviruses expressing either
the c-Myc-tagged reporter under the control of the Ngn3
promoter or a Ngn3-specific short hairpin (sh) interfering RNA
controlled by theCMV promoter, as in Xu et al. (2008). Transduc-
tion with the first construct confirmed both the re-expression of
Ngn3 and the specificity of Ngn3 promoter employed (Figures
S13–S15). Interestingly, Ngn3 knockdown caused a dramatic
reduction in the number of Ngn3+ (Figures 6A and 6E), insulin+Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc. 455
Figure 5. Progenitor Cells May Be Induced and Converted into Glucagon and Subsequently into Insulin-Expressing Cells
(A–I) After a pulse of BrdU at 3 weeks of age and examination a week later, a quantitative analysis established a 2.35-fold increase in the number of proliferating
cells in POE::Glucre pancreas compared to POE controls (A and B). Importantly, most BrdU-labeled cells are not detected within the islets, but rather near or
within the duct epithelium (B). It is worth noting that this location corresponds to the cluster of glucagon-producing cells consistently observed in this genotype.
Within the duct epithelium, scattered endocrine cells could be detected, some coexpressing the glucagon and sometimes somatostatin hormones (arrowheads456 Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc.
(Figure 6B, 6F, 6D, and 6H) and glucagon+ (Figures 6C and 6G)
cells, as well as in the level of transcripts encoding Ngn3, insulin,
and glucagon (Table S6).
To test whether glucagon signaling deficiency may also induce
the reactivation of Ngn3, in addition to POE::Glucre animals, we
analyzed glucagon receptor-deficient mice (characterized by an
a cell hyperplasia; Gelling et al. [2003]). When real-time RT-PCR
and counts of immunostained sections were combined (Tables
S3 and S4, Figure S16), an increase in Ngn3, but also in the
b cell regeneration-associated Reg3b (or INGAP; Rosenberg
[1998]) gene expression, was observed in both genotypes. Inter-
Figure 6. Knockdown of Ngn3 Prevents the Pax4-
Mediated b Cell Hyperplasia
Infection of POE::Glucre animals with lentiviruses producing
either an shRNA targeting Ngn3 transcripts (E–H) (Xu et al.,
2008) or producing a scrambled shRNA (based on the former;
A–D). Two weeks after infection, Ngn3 knockdown pancreata
(at the indicated magnifications) display an efficient 61% dimi-
nution in Ngn3 production (Xu et al., 2008) (A, E, and Table S6),
but also a 69% decrease in insulin- (B, F, D, and H) or
glucagon- (C and G) expressing cell numbers (Table S6)
compared to scramble-infected counterparts.
estingly, Ngn3 and Reg3b transcripts, as well as
Ngn3+ cell numbers, appeared to be dramatically
reduced in POE::Glucre animals supplemented
with glucagon for 3 weeks (Tables S3 and S4).
Thus, our data support the notion that the glucagon
deficiency mediated by the ectopic expression of
Pax4 results in Ngn3 expression and in the succes-
sive conversion of progenitor cells into glucagon-
and thereafter insulin-producing cells.
Pax4 Ectopic Expression Rescues
Streptozotocin-Induced Diabetes
Thus far, our data suggested that the forced expres-
sion of Pax4 in Pax6, Pdx1, or glucagon expression
domains ultimately led to the development of over-
sized islets of Langerhans mostly composed of
seemingly differentiated and functional b cells. We
reasoned that such cells might be capable of re-
placing lost b cells in diabetic mice. Hence, POE::
Glucre mice of different ages were injected with
a single dose of the b cell toxin STZ, and both blood
glucose levels as well as viability were monitored for
8 weeks (Figure 7A). Shortly after STZ injection, we
often observed a decrease in glycemia, most likely
caused by the discharge of insulin from killed b cells
(Figure 7A). A higher mortality rate was found
among animals older than 4 weeks, as compared to younger
mice. It should be noted that these animals were already hyper-
glycemic and weakened prior to STZ injection because of
a combined insulin insensitivity and b cell failure to optimally
respond to a glucose challenge (Figure S17). In contrast, in
4-week-old and younger STZ-treated animals, we noted
a normalization in blood glucose levels after a peak in glycemia
and survival rates reaching 41% 2 months after injection
(Figure 7A), while all controls died (data not shown). Immunohis-
tochemical analyses demonstrated that after the rapid oblitera-
tion of the b cell mass (Figures 7B–7E), a massive neogenesisin C and D). Along the same line, islet cells positive for the duct marker genes CK19 and SPP1 are observed adjacent to the duct epithelium (arrowheads in E and
F). Notably, the duct lining also appears to contain numerous cells positive for the proendocrine marker gene Ngn3 (G and H), but negative for Pdx1 (I).
(J–O) Infection of controls (K) and double-transgenic (L–O) pancreata with a construct containing a CMV promoter driving the constitutive expression of a c-Myc
tag (the latter being not expressed in wild-type tissues, J). Because of the method used, 2 weeks after infection, most exocrine cells are labeled by the virus,
whereas only very few islet cells are (islet underlined in K). Importantly, a majority of double-transgenic endocrine cells appear marked by the virus, suggesting
their ductal or acinar origin (L). These cells express the insulin hormone (M) and are b-galactosidase positive (N and O), indicating that they once expressed the
glucagon hormone. (H, I, M, and O: green fluorescence corresponding to residual GFP expression after bleaching of the sections.)Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc. 457
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of glucagon-expressing cells occurred, again near the duct lining
(Figures 7F–7I). Ten days after injection, only few insulin-
producing cells were detected (Figures 7F and 7G). However,
a steady increase in glucagon- and insulin-expressing cell
numbers was observed in the following days (Figure 7H). Approx-
imately 2 months after injection, POE::Glucre animals exhibited
almost normal-sized islets of Langerhans and normoglycemia
(Figure 7I). Interestingly, at that age, the b-galactosidase lineage
tracer was found to be uniformly distributed in islet cells
(Figure 7J), demonstrating that the insulin-producing cells in
these animals derived from cells that previously expressed
glucagon. These insulin+ cells displayed a b cell phenotype and
expressed a b cell-specific complement of transcription factors
(data not shown). Altogether, our analyses provide direct
evidence that, in STZ-treated mice, the ectopic expression of
Pax4 in a cells continuously converts them into b cells and
counters diabetes in animals younger than 4 weeks of age.
DISCUSSION
In this study, we report that the forced expression of the Pax4
gene in the mouse endocrine pancreas results in oversized islets
composed mainly of cells displaying a b cell phenotype. Our find-
ings are consistent with the induction of progenitor cells that
adopt an a cell identity as a consequence of decreased glucagon
levels, and subsequently acquire b cell features upon Pax4
ectopic expression, Ngn3 reactivation being instrumental in
this processes. The resulting b cells are functional at least at
an early age, and can repopulate the islets of diabetic mice to
normalize blood sugar levels.
Pax4 Promotes the b Cell Fate Specification during
Embryogenesis and Induces an a Cell-Mediated b Cell
Neogenesis Postpartum
The forced expression of Pax4, either in Pdx1+ pancreatic
progenitor cells (and ultimately in all pancreatic cells) or in
Pax6+ endocrine precursor cells (and ultimately in all islet cells),
results in the nearly exclusive specification of cells exhibiting
a b cell identity at the expense of the a, d, and PP cell lineages.
At birth, these animals display normal pancreas morphology,
unaffected exocrine tissue, and well-sized islets of Langerhans,
indicating that the main alterations observed are solely related
to the allocation of the different endocrine cell lineages during
embryonic development. This also suggests that Pax4 does
not alter the pancreatic exocrine differentiation program, butrather acts on the specification of endocrine progenitor cells
by promoting the acquisition of the b cell fate. Interestingly,
after birth, an age-dependent increase in islet size is evident
in pancreata ectopically expressing Pax4 that was attributed
to the continuous generation of cells displaying a b cell pheno-
type. In an effort to ascertain the origin of such cells, lineage-
tracing experiments were performed with POE::Glucre mice.
Our initial goal was to trigger the ectopic expression of Pax4
in adult glucagon-producing cells, but an inducible glucagon-
cre line is hitherto unavailable. Hence, the classical glucagon-
cre mouse line (Herrera, 2000) was used to induce Pax4
expression in glucagon-producing cells. It is important to note
that during embryogenesis, the glucagon gene is initially ex-
pressed in early endocrine cells often coexpressing additional
hormones, including insulin. However, by irreversibly tagging
the progeny of cells with the Cre/LoxP system, Herrera (2000)
demonstrated that mature glucagon- and insulin-producing
cells do not derive from cells that previously expressed insulin
or glucagon, respectively. Interestingly, lineage-tracing experi-
ments performed in POE::Glucre mice revealed that the vast
majority of newly formedb-galactosidase+/insulin+ cells originate
from cells that previously expressed glucagon (note that endog-
enous b-galactosidase/insulin+ cells remain detectable). Based
on these results, but also on the age-dependent increase of
b-galactosidase+ b cell numbers and the concomitant decrease
in a cell contents, the dramatic expansion of the b cell mass
throughout the postnatal life span of double-transgenic mice
was attributed to a continuous neoformation of b cells through
a cell redifferentiation rather than to the slow self-renewal
capacity of b cells (Dor et al., 2004). Although our findings are
in agreement with a putative neogenesis/conversion of somato-
statin- or PP-positive cells into b cells, testing of this hypothesis
will have to await the generation of somatostatin-cre and PP-cre
mice to allow lineage-tracing experiments.
Ngn3 Is Required for the Continuous Neogenesis
of a Cells Ultimately Acquiring a b Cell Phenotype
upon Pax4 Ectopic Expression
We demonstrate that glucagon supplementation reduces the
b cell hyperplasia in double-transgenic mice, most likely by
compensating the deficiency in circulating glucagon resulting
from the loss of a cells through Pax4-induced redifferentiation.
Interestingly, compromised glucagon signaling has previously
been associated with a cell neogenesis: both Glucagon receptor
(Gcgr)- and prohormone convertase 2 (Pcsk2)-deficient animalsFigure 7. Pax4 Ectopic Expression Promotes the Reconstitution of the Insulin-Expressing Cell Mass upon b Cell Depletion
(A) After streptozotocin injection at the indicated age (starting age), the glycemia and survival of the treated animals was followed for 2 months. Note that animals
older than 4 weeks of age become diabetic and die as a consequence of the obliteration of b cells, the same being true for all controls (data not shown). Impor-
tantly, in younger animals, a steady recovery leading to normoglycemia is observed next to a peak in glucose levels (all values are expressed as means ± standard
error of the mean).
(B–J) Islet cell contents in 4-week-old POE::Glucre streptozotocin- (D–J) or sham- (B and C) treated animals were quantified (see at the bottom of the concerned
pictures) 3 days (B–E), 10 days (F and G), 16 days (H), and 60 days (I and J) days after injection. Three days after injection, the b cell mass present in controls (B and
C) is almost entirely lost in streptozotocin-treated mice (D and E), the only insulin labeling being observed in areas devoid of nuclei, suggesting a detection of
hormone released from killed b cells. A 15% increase in glucagon-producing cells is highlighted 10 days after injection compared to controls, most of these cells
neighboring duct structures (G). Importantly, few insulin-labeled cells are detected (F). This trend is ascertained at day 16 (H) with a major increase in the insulin-
expressing cell number. A codetection with the glucagon hormone does not indicate any coexpression. Finally, at day 60, the b cell mass appears to be statis-
tically normal as compared to control animals (I compared to B and C), most of the cells present in the islet expressing the b-galactosidase enzyme marking
glucagon-producing cells (J).Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc. 459
display oversized islets, mainly composed of glucagon-
producing cells (Furuta et al., 1997; Gelling et al., 2003). Similar
to the present report, exogenous glucagon treatment signifi-
cantly reduced the endocrine cell hyperplasia in Pcsk2-deficient
animals (Blume et al., 1995; Petersson and Hellman, 1963; Webb
et al., 2002). Pcsk2 mutants were also found to contain
glucagon+ cells near the duct epithelium, and their contribution
to the neogenesis of the supernumerary glucagon+ cells was
suggested. Accordingly, our findings indicate that, upon Pax4
ectopic expression, a physiologically significant glucagon defi-
ciency activates a continuous compensatory response resulting
in a cell neogenesis, as seen in Gcgr and Pcsk2 mutant mice.
However, these cells are subsequently converted into b cells
upon Pax4 ectopic expression.
In animals ectopically expressing Pax4, but also in Gcgr
mutants, a reactivation of Ngn3, a gene normally exclusively
expressed during embryonic development of the pancreas
and required for the endocrine differentiation program, was
observed. However, because of the difficulties encountered to
detect Ngn3 transcripts or protein, the determination of the origin
of such Ngn3+ cell will require more elaborated lineage-tracing
experiments and/or more specific antibodies/in situ probes.
Interestingly, lentivirus-mediated cell tracing and knockdown
experiments showed that Ngn3 re-expression is in fact crucial
for the a cell-mediated b cell neogenesis. As important was
a recent report demonstrating that, upon pancreatic duct liga-
tion, facultative adult stem cells are activated along the lining
of duct epithelium (Dor and Melton, 2008; Xu et al., 2008). It
was also established that these cells reactivate Ngn3, differen-
tiate into endocrine cells, and contribute to the formation of over-
sized islets. In mice ectopically expressing Pax4, our results
suggest that duct-lining cells may represent the source of the
neogenerated glucagon-expressing cells. Although we cannot
exclude the contribution of acinar cells to this process, additional
evidence favor a duct-to-islet cell conversion mechanism: (1) the
continuous detection of neo-generated glucagon+ islet cells
adjacent to duct structures, (2) the active proliferation within
the duct epithelium and near the islet pole where non-b endocrine
cells accumulate, (3) the presence of glucagon+ endocrine cells
in the ductal lining, and (4) the detection of cells expressing duct
markers within the islet. Our findings are supported by recent
reports demonstrating the plasticity of pancreatic cells. For
instance, Melton and coworkers proved that acinar cells could
be reprogrammed into b cells upon the ectopic expression of
selected genes in vivo (Zhou et al., 2008), whereas Inada et al.
(2008) provided evidence that duct cells may give rise to endo-
crine and acinar cells in the adult pancreas. In agreement with
these, our analysis reveals that hypoglucagonemia activates
compensatory mechanisms provoking the conversion of
progenitor cells into a cells that subsequently acquire a b cell
phenotype upon Pax4 ectopic expression, these Ngn3-depen-
dent processes ultimately leading to the generation of oversized
islets of Langerhans.
Pax4 Ectopic Expression Rescues from Streptozotocin-
Induced Diabetes
We reasoned that the continuous b cell neogenesis observed in
double-transgenic animals might be able to rescue experimen-460 Cell 138, 449–462, August 7, 2009 ª2009 Elsevier Inc.tally induced diabetes. Therefore, the function of the newly
formed b cells was assessed in diabetic mice with more than
95% b cell loss after STZ treatment. No insulin supplement
was used to counter the sudden b cell loss, as the consequences
of exogenous insulin treatment on islet cells formation are hith-
erto unclear. Accordingly, a high lethality was expected, espe-
cially in older hyperglycemic and weakened mice. However,
while all control and double-transgenic mice older than 10 weeks
died, 41% of the younger animals survived during 2 months after
STZ injection. Closer examination revealed a progressive recon-
stitution of the islets and normalization of the glycemia and indi-
cated that the new insulin+ cells behaved as true b cells. Also
under these conditions, clusters of glucagon+ cells were de-
tected at one pole of the islets, adjacent to duct structures,
such cells subsequently adopting a b cell phenotype. Further-
more, the endocrine tissue in animals that died during the course
of these experiments showed significant b cell neogenesis, but,
most likely, not sufficient enough to allow survival.
The observation that only double-transgenic animals younger
than 4 weeks of age could survive STZ treatment was intriguing.
Interestingly, this age corresponds to the period when such
animals, initially hypoglycemic, progressively develop a hyper-
glycemic condition. While the low blood glucose levels observed
after birth can be easily explained by the b cell hyperplasia, the
development of a diabetic condition was unexpected: the steady
increase in insulin-producing cell content and the reduced
number of glucagon-expressing cells are in contrast with the
observed high glucose levels. In light of the data reported in
this study, it appears that the newly formed insulin-expressing
cells are functional for at least 4 weeks after birth and respond
normally to a glucose challenge. During this time, they express
all the b cell markers we tested and are negative for a, d, and
PP cell marker genes. However, glycemia, glucose tolerance,
insulin secretion, and insulin sensitivity deteriorate in older
animals despite a normal expression of a typical b cell comple-
ment of transcription factors, suggesting that older b cells fail
to trigger an optimal response upon glucose challenge. Interest-
ingly, these retain some capacity to secrete insulin when chal-
lenged with arginine or a long-acting GLP-1 analog. The reasons
for the establishment of such a condition are unclear, but may
result from progressive (1) b cell exhaustion, (2) b cell alterations,
(3) desensitization of the insulin receptor/pathway as a conse-
quence of increased insulin levels, and/or (4) unknown effects
induced by the decreased glucagon/somatostatin/PP hormone
contents. Defining the mechanisms involved would require
further work in which the impact of b cell hyperplasia, but also
of the decrease in a , d, and PP cell contents, could be modulated
and analyzed independently. It is interesting to note that younger
double transgenics subjected to streptozotocin treatment
display an extended life span in comparison to untreated coun-
terparts (data not shown). This indicates that the development of
the diabetic condition in these mice is not age-related, but may
rather depend on the islet hyperplasia state. Clearly, using
different activation times of exposure to Pax4 would allow us
to determine its long-term effect on islet function. Together,
our results suggest that the sole ectopic expression of Pax4 in
glucagon+ cells can, in younger animals, reverse the conse-
quences of streptozotocin-mediated diabetes through the
induction of a cell neogenesis and their ensuing conversion into
functional b cells. Based on these findings, we suggest that
drug-mediated modulation of Pax4 and/or its targets may open
new avenues for treatment of diabetes and, in addition, may
contribute to strategies aiming to differentiate b cells from
stem, progenitor, or other cell types.
EXPERIMENTAL PROCEDURES
Mouse Manipulations
The strategy used to generate the POE mouse line is depicted is Figure S1.
These mice were crossed with Pdx1-, Pax6-, Glucagon-, and Insulin-cre lines
(Ashery-Padan et al., 2004; Gu et al., 2002; Herrera, 2000) and genotyped with
a combination of fluorescence microscopy for GFP examination and genotyp-
ing PCR for cre and b-galactosidase genes.
So that the effects of glucagon on islet size could be assessed, mice were
injected intraperitoneally twice daily (every 12 hr) with 5 mg glucagon and sacri-
ficed after 3 weeks of treatment. For STZ-mediated diabetes induction,
a freshly prepared 50 mg/ml solution in 0.1 mol/l sodium citrate (pH 4.5) was
injected intraperitoneally (200 mg/kg). Lentivirus production and injection
were performed as described previously (Xu et al., 2008). Lastly, BrdU was in-
jected intraperitoneally (200 ml of 100 mg/ml) and was detected by immunohis-
tochemistry (Invitrogen).
Immunohistochemistry
Tissues were fixed in 4% PFA overnight at 4C and embedded in paraffin, and
8 mm sections were applied to slides. These sections were assayed as
described previously (Collombat et al., 2003). For coimmunofluorescence,
the GFP signal was bleached when necessary, as described (Collombat
et al., 2007). The primary antibodies used were the following: mouse mono-
clonal anti-insulin, anti-glucagon (1/1000, Sigma), anti-Ngn3 (1/2000,
1F25A1B3, BCBC Antibody Core), anti-c-Myc (1/100, Abcam); guinea pig
anti-insulin, anti-glucagon (1/1000, Sigma); rabbit anti-somatostatin (1/600,
Dako), anti-PP (1/200, Dako), anti-Nkx6.1 (1/3000), anti-Nkx2.2 (1/1000, kindly
provided by T. Jessell), anti-Pax6 (1/500, Chemicon), anti-Pax4 (1/500), and
anti-Arx (1/1000); chicken anti-b-galactosidase (1/500, Biozol); and goat
anti-Ngn3 (1/1000, kindly provided by M. Sander). The secondary antibodies
(1/1000, Molecular Probes) used were the following: 594-alexa anti-mouse,
488-alexa anti-mouse, 594-alexa anti-rabbit, 488-alexa anti-rabbit, 594-alexa
anti-guinea pig, and 488-alexa anti-guinea pig. Pictures were processed by
confocal microscopy. For quantification purpose, stained cells were counted
manually on every tenth section, and the count was reported to the pancreatic
area estimated in silico.
Glucose Challenge and Circulating Glucose or Insulin Level
Measurements
For glucose challenge tests, six mice per genotype were fasted for 24 hr and
injected intraperitoneally with glucose (2 g/kg), and blood glucose levels
were measured 0, 30, 60, 90, 120, 150, and 210 min afterward. At each time
point, one animal per genotype was sacrificed immediately after glycemia
assessment for serum insulin level determination with RIA (Linco). Glucose
levels (mg/dl) were determined with the One Touch Glucose Monitoring Kit
(Johnson & Johnson).
Data Analysis
All values are depicted as mean ± standard error of the mean from at least three
independent experiments and considered significant if p < 0.05. All data were
statistically analyzed by multivariate comparison (two-way ANOVA) with Bon-
ferroni correction or one-way ANOVA with Newman-Keuls correction.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 17
figures, seven tables, and two movies and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(09)00639-4.ACKNOWLEDGMENTS
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